We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Insulet (PODD - Free Report) to post quarterly earnings of $1.05 per share in its upcoming report, which indicates a year-over-year decline of 25%. Revenues are expected to be $581.65 million, up 14.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Insulet metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Revenue- Total Omnipod' to reach $575.12 million. The estimate indicates a change of +14.8% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Drug Delivery' of $6.07 million. The estimate points to a change of -31% from the year-ago quarter.
Analysts predict that the 'Revenue- International Omnipod' will reach $140.18 million. The estimate indicates a year-over-year change of +31.8%.
The combined assessment of analysts suggests that 'Revenue- U.S. Omnipod' will likely reach $434.94 million. The estimate indicates a change of +10.2% from the prior-year quarter.
Over the past month, Insulet shares have recorded returns of +3.4% versus the Zacks S&P 500 composite's +4.9% change. Based on its Zacks Rank #3 (Hold), PODD will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics
Wall Street analysts expect Insulet (PODD - Free Report) to post quarterly earnings of $1.05 per share in its upcoming report, which indicates a year-over-year decline of 25%. Revenues are expected to be $581.65 million, up 14.1% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Insulet metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Revenue- Total Omnipod' to reach $575.12 million. The estimate indicates a change of +14.8% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Drug Delivery' of $6.07 million. The estimate points to a change of -31% from the year-ago quarter.
Analysts predict that the 'Revenue- International Omnipod' will reach $140.18 million. The estimate indicates a year-over-year change of +31.8%.
The combined assessment of analysts suggests that 'Revenue- U.S. Omnipod' will likely reach $434.94 million. The estimate indicates a change of +10.2% from the prior-year quarter.
View all Key Company Metrics for Insulet here>>>
Over the past month, Insulet shares have recorded returns of +3.4% versus the Zacks S&P 500 composite's +4.9% change. Based on its Zacks Rank #3 (Hold), PODD will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>